The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR+ MBC).
 
Amit L Jain
No Relationships to Disclose
 
Janice Nhan Mullins
No Relationships to Disclose
 
Kelsey Anne Poorman
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Amina Chaudhry
No Relationships to Disclose
 
Harsha Avinash Ranganath
No Relationships to Disclose
 
Emily McCollum Miller
No Relationships to Disclose
 
Poojitha Valasareddy
No Relationships to Disclose
 
Justin R Smith
No Relationships to Disclose
 
Julie Ryder
No Relationships to Disclose
 
Michelle Winerip
Employment - Caris Life Sciences
Research Funding - Caris Life Sciences
 
Lee S. Schwartzberg
Stock and Other Ownership Interests - Vector Oncology
Honoraria - Amgen; E.R. Squibb Sons, LLC; Genentech; Helsinn Healthcare; NanoString Technologies; Napo Pharmaceuticals; Novartis; Pfizer; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Caris Life Sciences; E.R. Squibb Sons, LLC; Genentech; Genomic Health; Helsinn Therapeutics; Lilly; Novartis; Pfizer; Roche; Spectrum Pharmaceuticals; Tesaro; Vector Oncology
Research Funding - Amgen (Inst); Bayer Health (Inst); E.R. Squibb Sons, LLC (Inst); E.R. Squibb Sons, LLC (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Tesaro (Inst)
 
Gregory A. Vidal
Consulting or Advisory Role - Lilly; Pfizer
Speakers' Bureau - AstraZeneca; Pfizer
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Lilly; Pfizer; Puma Biotechnology; Tesaro